Clinical Trial Update: Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD) [Phase 2]

View source ↗

Summary

Phase 2a extension study of ataluren (PTC124) in Duchenne Muscular Dystrophy was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• ataluren (ataluren)

Snippet

Sponsor: PTC Therapeutics | Conditions: Duchenne Muscular Dystrophy | Phase 2 | Status: TERMINATED | Results posted: 2020-10-29